Search the Newsreel

Should iRhythm’s Stronger Q2 2026 Results and Higher Guidance Amid Class Action Settlement Require Action From iRhythm Holdings (IRTC) Investors?

RHYTHM PHARMACEUTICALS, INC. SEC Filing (Aug 10, 2026)

This article details an SEC Form 144 filing by RHYTHM PHARMACEUTICALS, INC. (RYTM) on August 10, 2026. The filing indicates a proposed sale of 3,520 common shares with an aggregate market value of $407,017.60, acquired through the exercise of stock options on the same …

Why iRhythm (IRTC) Stock Is Trading Up Today

Why iRhythm (IRTC) Stock Is Trading Up Today What Happened? Shares of medical technology company iRhythm Technologies (NASDAQ:IRTC) jumped 2% in the afternoon session after the company reported strong second-quarter financial results that surpassed expectations and raised its full-year guidance. The cardiac monitoring company …

iRhythm Technologies (NASDAQ:IRTC) Stock Price Expected to Rise, Truist Financial Analyst Says

Truist Financial has increased its price target for iRhythm Technologies (NASDAQ:IRTC) from $160 to $168, maintaining a "buy" rating and indicating a potential upside of 34.59%. This positive outlook aligns with a "Moderate Buy" consensus rating from MarketBeat analysts, despite some recent target reductions …

RYTM - High-Growth Emerging Commercial Stage Biotech

Rhythm Pharmaceuticals (RYTM) is presented as a high-growth commercial-stage biotech company focused on orphan neuroendocrine disorders, particularly those related to MC4R pathway dysfunction (genetic obesity). The article highlights the company's strong Q2 2026 results for IMCIVREE, with better-than-expected patient uptake and international growth, along …

IRhythm to Gain From VitalConnect Deal, Rising Margins, Oppenheimer Says

Oppenheimer expects iRhythm Technologies to benefit from its acquisition of VitalConnect, which will add a significant product to its portfolio and is expected to be immediately accretive to margins. The firm reiterates an Outperform rating and a $170 price target for iRhythm, citing potential …

iRhythm Q2 Earnings Beat Estimates on Volume Growth, '26 View Raised

iRhythm Holdings, Inc. IRTC reported adjusted earnings per share of 58 cents in the second quarter of 2026, against an adjusted loss per share of 32 cents a year ago. The figure beat the Zacks Consensus Estimate by 5900%. GAAP loss per share for …

Why iRhythm (IRTC) Shares Are Trading Lower Today

Shares of iRhythm Technologies (IRTC) fell after an analyst significantly cut their price target on the stock, despite the company reporting strong quarterly earnings and raising its full-year revenue guidance. Truist lowered its price target to $18 from $160, even while maintaining a "Buy" …

IRhythm grows heart monitoring leadership with $288M VitalConnect buy

IRhythm announced its acquisition of VitalConnect for $287.5 million to expand its mobile cardiac telemetry (MCT) capabilities. This acquisition is expected to unlock access to an additional $500 million market opportunity within the $1 billion cardiac monitoring market. While IRhythm remains committed to securing …

Algorhythm Holdings Inc (RIME) Stock News Today

This article provides recent stock news for Algorhythm Holdings Inc (RIME), including its current stock price and market capitalization. It highlights a specific news item about a statement from Algorhythm triggering a 'Black Thursday' for global assets, published on February 13. The page also …

IRTC Q2 Deep Dive: Product Portfolio Expansion and Margin Gains Highlight Quarter

IRTC Q2 Deep Dive: Product Portfolio Expansion and Margin Gains Highlight Quarter Medical technology company iRhythm Technologies (NASDAQ:IRTC) reported Q2 CY2026 results exceeding the market's revenue expectations , with sales up 20.1% year on year to $224.2 million. The company expects the full year's …

Kuehn Law Encourages Investors of iRhythm Technologies, Inc. to Contact Law Firm

Kuehn Law, PLLC is investigating iRhythm Technologies, Inc. (IRTC) for potential breaches of fiduciary duties by its officers and directors. The investigation stems from allegations that the company misrepresented the Zio AT monitor's capabilities and market penetration, leading to artificially inflated stock prices. The …

Irhythm Technologies Boosts Outlook, Expands Cardiac Monitoring Platform

iRhythm Technologies (IRTC) recently settled a patent dispute for $50 million and announced strong Q2 2026 results, including a 20.1% revenue increase and improved margins. The company also secured FDA clearance for a new algorithm and plans to acquire Vital Connect for $287.5 million …

Rhythm Pharmaceuticals (RYTM) Reports Promising RM 718 Data, Is The Upside Already Priced In?

Algorhythm Holdings Inc (RIME) Earnings Forecast: Future EPS & Revenue Growth Estimates

This article provides an earnings forecast for Algorhythm Holdings Inc (RIME), noting a current earnings forecast score of 8.00 and an average price target of $5.00 from one analyst. The analyst recommends a "Buy" rating, indicating a potential upside of over 1000%. The report …

iRhythm Technologies (NASDAQ:IRTC) Rating Lowered to "Hold" at Wall Street Zen

Wall Street Zen has downgraded iRhythm Technologies (NASDAQ:IRTC) to a "Hold" rating from "Buy," despite the company's strong Q2 results and a broader analyst consensus of "Moderate Buy." iRhythm reported earnings of $0.58 per share against an expected loss and saw revenue increase by …

iRhythm Technologies, Inc. Q2 2026 Earnings Call Summary

iRhythm Technologies reported its seventh consecutive quarter of over 20% revenue growth, driven by strong demand across cardiology, primary care, and international markets. The company announced the acquisition of VitalConnect to expand into new cardiac monitoring modalities and raised its full-year 2026 revenue guidance …

Why iRhythm Holdings (IRTC) Is Up 9.1% After Raising 2026 Outlook and Advancing Legal Settlement – And What's Next

In early August 2026, iRhythm Holdings reported second-quarter 2026 results showing sales rising to US$224.17 million and net loss narrowing to US$0.381 million, while also increasing its full-year 2026 revenue guidance to US$880 million–US$890 million and announcing a proposed US$45.00 million securities class action …

iRhythm (IRTC) Stock Ignores Record Margins And Free Cash Flow

iRhythm advances cardiac monitoring provision with $287.5m VitalConnect acquisition

iRhythm has announced the acquisition of VitalConnect for $287.5 million, a move aimed at expanding its cardiac monitoring platform across various healthcare settings. The deal, expected to close by the end of 2026, combines cash and iRhythm common stock. This acquisition is anticipated to …

iRhythm Technologies Inc (IRTC) Stock News Today

This article provides current stock information for iRhythm Technologies Inc (IRTC), including its stock price, market capitalization, and a note that more news is coming soon. It also lists various financial and analytical tools available on the TradingKey platform for investors.

Truist Securities Adjusts IRhythm Technologies PT to $168 From $160, Maintains Buy Rating

Truist Securities has increased its price target for iRhythm Technologies (IRTC) to $168 from $160, while reiterating a Buy rating on the stock. This adjustment suggests a positive outlook on the company's future performance by the investment bank.

iRhythm Holdings, Inc. 2026 Q2 - Results - Earnings Call Presentation (NASDAQ:IRTC) 2026-08-07

Pyrophyte Acquisition Corp II (PAII) Stock News Today

Pyrophyte Acquisition Corp II (PAII) Earnings Forecast: Future EPS & Revenue Growth Estimates

iRhythm Technologies (NASDAQ:IRTC) Sees Unusually-High Trading Volume Following Strong Earnings

Needham cuts iRhythm Technologies stock price target on lower multiple

Needham has lowered its price target for iRhythm Technologies (NASDAQ:IRTC) to $192 from $255, while maintaining a Buy rating. The adjustment comes despite iRhythm exceeding Q2 2026 revenue expectations and raising its full-year guidance, partly due to the acquisition of VitalConnect which is expected …

IRTC Looks 22.6% Undervalued on GF Value™

iRhythm Technologies, Inc. (IRTC) reported strong Q2 revenue growth of 20.1% year-over-year, leading to raised full-year guidance and a strategic acquisition to expand its cardiac monitoring capabilities. Despite being unprofitable, the company is considered 22.6% undervalued based on its GF Value™ and shows strong …

Acrophyte Hospitality Trust (SGX:XZL) Stock Yield Appeal Meets Cash Flow Strain

iRhythm Holdings Inc (IRTC) (Q2 2026) Earnings Call Highlights: Record Profitability and ...

This article first appeared on GuruFocus. Release Date: August 06, 2026 For the complete transcript of the earnings call, please refer to the full earnings call transcript. Positive Points iRhythm Holdings Inc (NASDAQ:IRTC) delivered its seventh consecutive quarter of revenue growth above 20%, with …

Earnings call transcript: iRhythm tops revenue view in Q2 2026 and stock rises

iRhythm Technologies (IRTC) reported strong Q2 2026 results, exceeding revenue forecasts and demonstrating significant margin expansion, leading to a stock increase. The company announced the acquisition of VitalConnect, which is expected to expand its cardiac monitoring offerings and accelerate its entry into new markets …

(IRTC) IRhythm Technologies Expects 2026 Revenue Range $880M - $890M, vs. FactSet Est of $881.1M

iRhythm Technologies (IRTC) has announced its revenue expectations for 2026, forecasting a range of $880 million to $890 million. This projection is in line with FactSet's estimated revenue of $881.1 million for the same period. The company also reported its Q2 2026 earnings, with …

iRhythm Holdings, Inc. Quarterly Earnings Report

iRhythm (NASDAQ:IRTC) Beats Q2 CY2026 Sales Expectations

iRhythm (NASDAQ:IRTC) Beats Q2 CY2026 Sales Expectations Medical technology company iRhythm Technologies (NASDAQ:IRTC) beat Wall Street's revenue expectations in Q2 CY2026, with sales up 20.1% year on year to $224.2 million. The company expects the full year's revenue to be around $885 million, close …

How Investors May Respond To Rhythm Pharmaceuticals (RYTM) Q2 Results And Early RM-718 Obesity Data

Rhythm Pharmaceuticals reported stronger Q2 2026 revenues for IMCIVREE and promising early Phase 2 data for its new drug RM-718 for acquired hypothalamic obesity. The article discusses how these developments may refine the company's investment narrative, which currently balances growth from its rare-disease franchise …

iRhythm to Acquire VitalConnect, Expanding Its Cardiac Monitoring Platform Across Ambulatory, Inpatient and Hospital-to-Home Care

iRhythm Holdings, Inc. announced its definitive agreement to acquire VitalConnect for approximately $287.5 million, comprising cash and iRhythm common stock. This acquisition is expected to broaden iRhythm's cardiac monitoring platform by adding mobile cardiac telemetry and multi-vitals monitoring capabilities, expanding its addressable market across …